Raymond James & Associates Akebia Therapeutics, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 42,311 shares of AKBA stock, worth $127,779. This represents 0.0% of its overall portfolio holdings.

Number of Shares

42,311

Previous 51,239 17.42%

Holding current value

$127,779

Previous $52,000 5.77%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$0.94 - $1.55 $8,392 - $13,838	-8,928 Reduced 17.42%	42,311 $55,000
Q2 2024 Jul 19, 2024	BUY	$0.86 - $1.63 $8,600 - $16,299	10,000 Added 24.25%	51,239 $52,000
Q1 2024 Apr 22, 2024	BUY	$1.27 - $2.24 $14,378 - $25,361	11,322 Added 37.84%	41,239 $75,000
Q4 2023 Jan 16, 2024	BUY	$0.8 - $1.28 $7,756 - $12,410	9,696 Added 47.95%	29,917 $37,000
Q3 2023 Oct 24, 2023	BUY	$0.87 - $1.84 $7,498 - $15,858	8,619 Added 74.29%	20,221 $23,000
Q2 2023 Jul 25, 2023	BUY	$0.51 - $1.43 $5,917 - $16,590	11,602 New	11,602 $10,000
Q1 2022 May 11, 2022	SELL	$0.72 - $2.93 $7,560 - $30,765	-10,500 Reduced 44.87%	12,900 $9,000
Q4 2021 Feb 08, 2022	BUY	$2.26 - $3.34 $2,271 - $3,356	1,005 Added 4.49%	23,400 $53,000
Q2 2021 Aug 11, 2021	BUY	$2.83 - $4.2 $633 - $940	224 Added 1.01%	22,395 $85,000
Q1 2021 May 14, 2021	BUY	$2.92 - $5.06 $5,256 - $9,108	1,800 Added 8.84%	22,171 $75,000
Q4 2020 Feb 12, 2021	BUY	$2.22 - $3.78 $21,645 - $36,855	9,750 Added 91.8%	20,371 $57,000
Q3 2020 Nov 04, 2020	SELL	$2.39 - $13.08 $11,101 - $60,756	-4,645 Reduced 30.43%	10,621 $27,000
Q2 2020 Jul 28, 2020	BUY	$6.67 - $13.58 $8,877 - $18,074	1,331 Added 9.55%	15,266 $207,000
Q1 2020 Apr 21, 2020	SELL	$4.1 - $10.24 $9,733 - $24,309	-2,374 Reduced 14.56%	13,935 $106,000
Q4 2019 Feb 12, 2020	SELL	$3.16 - $6.73 $15,935 - $33,939	-5,043 Reduced 23.62%	16,309 $103,000
Q3 2019 Nov 07, 2019	BUY	$3.55 - $5.4 $6,574 - $10,000	1,852 Added 9.5%	21,352 $84,000
Q2 2019 Aug 06, 2019	BUY	$4.1 - $8.05 $79,950 - $156,975	19,500 New	19,500 $94,000
Q3 2018 Nov 14, 2018	SELL	$7.44 - $10.65 $287,913 - $412,133	-38,698 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $576 - $714	-63 Reduced 0.16%	38,698 $386,000
Q1 2018 May 14, 2018	SELL	$9.53 - $15.68 $7,604 - $12,512	-798 Reduced 2.02%	38,761 $369,000
Q4 2017 Feb 14, 2018	BUY	$14.24 - $19.59 $38,747 - $53,304	2,721 Added 7.39%	39,559 $588,000
Q3 2017 Nov 13, 2017	BUY	$13.06 - $19.67 $4,192 - $6,314	321 Added 0.88%	36,838 $725,000
Q2 2017 Aug 14, 2017	BUY	N/A	36,517	36,517 $525,000

Others Institutions Holding AKBA

# of Institutions

165

Shares Held

95.6M

Call Options Held

98.6K

Put Options Held

320K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $555M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Akebia Therapeutics, Inc. Transaction History